226 related articles for article (PubMed ID: 29263653)
21. Olaratumab in the management of advanced soft tissue sarcoma.
Zobniw CM; Trinh VA; Posey K; Somaiah N
J Oncol Pharm Pract; 2019 Mar; 25(2):442-448. PubMed ID: 30032714
[TBL] [Abstract][Full Text] [Related]
22. Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.
Mo G; Baldwin JR; Luffer-Atlas D; Ilaria RL; Conti I; Heathman M; Cronier DM
Clin Pharmacokinet; 2018 Mar; 57(3):355-365. PubMed ID: 28620891
[TBL] [Abstract][Full Text] [Related]
23. Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma : Data of real-world utilization in Austria.
Seeber A; Weiss L; Romeder F; Szkandera J; Kuehr T; Kostner S; Pichler P; Jaeger T; Kocher F; Greil R; Brodowicz T
Wien Klin Wochenschr; 2021 Jan; 133(1-2):21-25. PubMed ID: 31620878
[TBL] [Abstract][Full Text] [Related]
24. Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
Lowery CD; Blosser W; Dowless M; Knoche S; Stephens J; Li H; Surguladze D; Loizos N; Luffer-Atlas D; Oakley GJ; Guo Q; Iyer S; Rubin BP; Stancato L
Clin Cancer Res; 2018 Feb; 24(4):847-857. PubMed ID: 29191969
[No Abstract] [Full Text] [Related]
25. Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma.
Jones RL; Mo G; Baldwin JR; Peterson PM; Ilaria RL; Conti I; Cronier DM; Tap WD
Cancer Chemother Pharmacol; 2019 Jan; 83(1):191-199. PubMed ID: 30406840
[TBL] [Abstract][Full Text] [Related]
26. Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma.
Martin-Liberal J; Pérez E; García Del Muro X
Expert Opin Investig Drugs; 2019 Jan; 28(1):39-50. PubMed ID: 30513001
[TBL] [Abstract][Full Text] [Related]
27. Developments in the management of advanced soft-tissue sarcoma - olaratumab in context.
Moroncini G; Maccaroni E; Fiordoliva I; Pellei C; Gabrielli A; Berardi R
Onco Targets Ther; 2018; 11():833-842. PubMed ID: 29497315
[TBL] [Abstract][Full Text] [Related]
28. Advances of systemic treatment for adult soft-tissue sarcoma.
Liu W; Jiang Q; Zhou Y
Chin Clin Oncol; 2018 Aug; 7(4):42. PubMed ID: 30173532
[TBL] [Abstract][Full Text] [Related]
29. PDGFRA Antibody for Soft Tissue Sarcoma.
Klug LR; Heinrich MC
Cell; 2017 Feb; 168(4):555. PubMed ID: 28187274
[TBL] [Abstract][Full Text] [Related]
30. Challenges of Using ICD-9-CM and ICD-10-CM Codes for Soft-Tissue Sarcoma in Databases for Health Services Research.
Hess LM; Zhu YE; Sugihara T; Fang Y; Collins N; Nicol S
Perspect Health Inf Manag; 2019; 16(Spring):1a. PubMed ID: 31019431
[TBL] [Abstract][Full Text] [Related]
31. Olaratumab: A New Strategy in the Treatment of Advanced Soft-Tissue Sarcoma.
Moore DC; Lavery LA
J Adv Pract Oncol; 2018 Mar; 9(2):235-240. PubMed ID: 30588358
[TBL] [Abstract][Full Text] [Related]
32. Revocation of the conditional marketing authorisation of a cancer medicine: The olaratumab experience.
Herold R; Camarero J; Melchiorri D; Sebris Z; Enzmann H; Pignatti F
Eur J Cancer; 2019 Dec; 123():25-27. PubMed ID: 31655357
[No Abstract] [Full Text] [Related]
33. The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model.
Higuchi T; Miyake K; Sugisawa N; Oshiro H; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1075-1082. PubMed ID: 30929053
[TBL] [Abstract][Full Text] [Related]
34. Investigating a chimeric anti-mouse PDGFRα antibody as a radiosensitizer in primary mouse sarcomas.
Song EJ; Ashcraft KA; Lowery CD; Mowery YM; Luo L; Ma Y; Campos LDS; Cardona DM; Stancato L; Kirsch DG
EBioMedicine; 2019 Feb; 40():224-230. PubMed ID: 30711517
[TBL] [Abstract][Full Text] [Related]
35. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.
Young RJ; Natukunda A; Litière S; Woll PJ; Wardelmann E; van der Graaf WT
Eur J Cancer; 2014 Dec; 50(18):3178-86. PubMed ID: 25459395
[TBL] [Abstract][Full Text] [Related]
36. Aldoxorubicin for the treatment of soft tissue sarcoma.
Sachdev E; Sachdev D; Mita M
Expert Opin Investig Drugs; 2017 Oct; 26(10):1175-1179. PubMed ID: 28846045
[TBL] [Abstract][Full Text] [Related]
37. Targeted treatments of sarcomas and connective tumors beside gastrointestinal stromal tumor.
Martin-Broto J; Hindi N
Curr Opin Oncol; 2016 Jul; 28(4):338-44. PubMed ID: 27166665
[TBL] [Abstract][Full Text] [Related]
38. Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.
Reed D; Altiok S
Cancer Control; 2011 Jul; 18(3):188-95. PubMed ID: 21666581
[TBL] [Abstract][Full Text] [Related]
39. Evolving Treatment of Soft Tissue Sarcoma.
George S
J Natl Compr Canc Netw; 2017 May; 15(5S):733-736. PubMed ID: 28515258
[TBL] [Abstract][Full Text] [Related]
40. Economic evaluation of the GENESIS-SEFH report of olaratumab with doxorubicin in soft tissue sarcoma in advanced stages.
Del Río-Valencia JC; Asensi-Díez R; Villalobos-Torres L; Clopés-Estela A; Fraga-Fuentes MªD
Farm Hosp; 2018 Sep; 42(5):204-211. PubMed ID: 30173639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]